Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this double-blind randomized clinical trial is to determine the effects of Melatonin on cardiovascular disease risk factors, bone metabolism markers, serum concentrations of advanced glycated end products and quality of life in peritoneal dialysis patients. Forty patients from peritoneal dialysis centers will randomly assign to either Melatonin or placebo group. The patients in Melatonin group will receive 5 mg Melatonin (as 1 tablet) daily for 10 weeks, while the placebo group will receive identical placebo. At the baseline and the end of the study,7 ml blood will be collected from each patient after a 12-14-hours fasting and Serum concentrations of malondialdehyde; high sensitivity c-reactive protein; Soluble intercellular adhesion molecule-1; glucose; pentosidine; carboxy-methyl lysine; Procollagen 1 Intact N-Terminal Propeptide; Tartrate-resistant acid phosphatase 5b; osteoprotegerin; Receptor activator of nuclear factor kappa-Β ligand; Intact parathyroid hormone; triglyceride; total cholesterol; High-density lipoprotein cholesterol; low-density lipoprotein cholesterol; lipoprotein-a; albumin; calcium; phosphorous; and also systolic blood pressure; diastolic blood pressure and questionnaires including quality of life; quality of sleep and depression will be assessed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Melatonin | Active Comparator |
| |
| placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Melatonin | Dietary Supplement | 5 mg Melatonin in one tablet, 30 minutes before night sleep |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Lp (a) | Serum concentrations of lipoprotein-a | 10 weeks |
| MDA | Serum concentrations of malondialdehyde | 10 weeks |
| hs-CRP | Serum concentrations of high sensitivity c-reactive protein | 10 weeks |
| sICAM-1 | Serum concentrations of Soluble intercellular adhesion molecule-1 | 10 weeks |
| glucose | serum concentration of fasting glucose | 10 weeks |
| pentosidine | serum concentration of pentosidine | 10 weeks |
| carboxy-methyl lysine | serum concentration of carboxy-methyl lysine | 10 weeks |
| P1NP | serum concentration of Procollagen 1 Intact N-Terminal Propeptide | 10 weeks |
| Osteoprotegerin | Serum concentrations of Osteoprotegerin |
| Measure | Description | Time Frame |
|---|---|---|
| albumin | Serum concentrations of albumin | 10 weeks |
| calcium | Serum concentrations of calcium | 10 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| zahra yari | Contact | +982122357484 | zahrayari_nut@yahoo.com |
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41125682 | Derived | Movahedian M, Tabibi H, Atabak S, Hedayati M, Najafi I, Seyrafian S, Rouhani MH. Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial. Sci Rep. 2025 Oct 22;15(1):36896. doi: 10.1038/s41598-025-20792-2. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008550 | Melatonin |
| ID | Term |
|---|---|
| D014363 | Tryptamines |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| placebo |
| Other |
1 tablet of placebo (starch) |
|
| 10 weeks |
| TRACP5b | Serum concentrations of Tartrate-resistant acid phosphatase 5b | 10 weeks |
| RANKL | Serum concentrations of Receptor activator of nuclear factor kappa-Β ligand | 10 weeks |
| Systolic blood pressure | Systolic blood pressure (mmHg) | 10 weeks |
| Diastolic blood pressure | Diastolic blood pressure (mmHg) | 10 weeks |
| triglyceride | Serum concentrations of triglyceride | 10 weeks |
| Total cholesterol | Serum concentrations of total cholesterol | 10 weeks |
| HDL-C | Serum concentrations of High-density lipoprotein cholesterol | 10 weeks |
| LDL-C | Serum concentrations of low-density lipoprotein cholesterol | 10 weeks |
| Quality of life index (KDQOL) questionnaire | Filling the kidney disease quality of life index (KDQOL) questionnaire | 10 weeks |
| the Beck depression test | Filling the Beck depression test | 10 weeks |
| Quality of sleep Pittsburgh Sleep Quality Index (PSQI) questionnaire | Filling the Pittsburgh Sleep Quality Index (PSQI) questionnaire | 10 weeks |
| phosphorous | Serum concentrations of phosphorous | 10 weeks |
| iPTH | Serum concentrations of Intact parathyroid hormone | 10 weeks |
| D006571 | Heterocyclic Compounds |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |